Demand for Cannabis Use Disorder Treatment in Japan 2025 to 2035

The Japan cannabis use disorder treatment demand is valued at USD 83.7 million in 2025 and is forecasted to reach USD 118.4 million by 2035, reflecting a CAGR of 3.5%. Demand is influenced by increased identification of substance-use disorders, expansion of psychiatric screening programmes, and wider recognition of cannabis-related dependence as a public health concern. Rising utilization of structured therapy pathways, integration of addiction services within mental-health systems, and continued policy attention toward early intervention support stable treatment uptake across clinical settings. Clinical interventions for marijuana-related dependence account for the largest share. Treatment centers rely on cognitive behavioural therapy, motivational enhancement strategies, relapse-prevention frameworks, and rehabilitation support designed for long-term behavioural management. These approaches remain central as Japan maintains strict regulations on cannabis use and prioritizes non-pharmacological treatment pathways for affected individuals.

Kyushu & Okinawa, Kanto, and Kansai register the highest utilization levels due to their extensive hospital networks, specialized psychiatric facilities, and established mental-health support infrastructure. These regions also host community-based rehabilitation programmes and counselling services that strengthen treatment accessibility. Key organizations include the National Center of Neurology and Psychiatry (NCNP), Japan Alcohol and Drug Addiction Rehabilitation Center (DARC Network), Japanese Society of Psychiatry and Neurology (JSPN), Prefectural Mental Health and Welfare Centers, and private psychiatric hospitals and addiction clinics. These institutions provide assessment, counselling, rehabilitation, and long-term support for individuals with cannabis use disorder.

Quick Stats for Japan Cannabis Use Disorder Treatment Demand

• Japan Cannabis Use Disorder Treatment Sales Value (2025): USD 83.7 million
• Japan Cannabis Use Disorder Treatment Forecast Value (2035): USD 118.4 million
• Japan Cannabis Use Disorder Treatment Forecast CAGR (2025–2035): 3.5%
• Leading Type in Japan Cannabis Use Disorder Treatment Demand: Marijuana
• Key Growth Regions in Japan Cannabis Use Disorder Treatment Demand: Kyushu & Okinawa, Kanto, Kansai
• Top Players in Japan Cannabis Use Disorder Treatment Demand: National Center of Neurology and Psychiatry (NCNP), Japan Alcohol and Drug Addiction Rehabilitation Center (DARC Network), Japanese Society of Psychiatry and Neurology (JSPN), Prefectural Mental Health and Welfare Centers, Private psychiatric hospitals and addiction clinics

What is the Growth Forecast for Cannabis Use Disorder Treatment Industry in Japan through 2035?

Growth rate volatility in Japan’s cannabis-use-disorder treatment segment remains low because demand is shaped primarily by regulatory structures, limited prevalence, and controlled clinical pathways. Annual variation is narrow in the early period as treatment access is tied to specialist care settings, where patient volumes change slowly and referral patterns remain stable. Public-health programmes and mental-health services follow fixed protocols, which reinforces predictable utilization.

Mid-period volatility remains limited because the segment expands within a tightly regulated environment. Awareness initiatives, clinician training, and incremental development of structured treatment frameworks contribute to steady but modest increases. Since cannabis use in Japan remains low by international comparison, shifts in patient numbers tend to be gradual, preventing sharp year-to-year swings. Institutional adoption of treatment models also progresses at a controlled pace due to strict compliance expectations.

Late-period volatility stays contained as treatment services mature and follow established behavioural-health processes. Growth depends mainly on incremental increases in screening, early-intervention programmes, and integration with broader addiction-care systems. These changes move slowly and keep volatility compressed.

Japan Cannabis Use Disorder Treatment Key Takeaways

Why is the Demand for Cannabis Use Disorder Treatment in Japan Growing?

Demand for cannabis use disorder treatment in Japan is increasing because healthcare providers and public health agencies are observing gradual growth in cases linked to recreational experimentation, illicit product availability and rising awareness of dependency risks. Although overall cannabis use remains low compared with many countries, enforcement data and clinical reports show more individuals experiencing psychological dependence, withdrawal symptoms and social or occupational challenges that require structured intervention. Hospitals and mental health clinics integrate screening tools into psychiatric and addiction services, which increases detection.

Educational campaigns encourage families to seek early clinical support, strengthening demand for counselling, behavioural therapy and relapse-prevention programmes. Universities and community centers also promote awareness of substance-related risks, prompting more referrals to treatment facilities. Constraints include limited number of specialized addiction-treatment programmes for cannabis specifically, social stigma that discourages early help-seeking, and lack of broad public understanding of cannabis-related mental health symptoms. Regulatory restrictions on research and treatment innovation also slow expansion of evidence-based approaches. Some individuals avoid formal services due to concerns about legal consequences or privacy.

Which Substance Types, Treatment Approaches, and End Users Lead Demand for Cannabis Use Disorder Treatment in Japan?

Demand for cannabis use disorder treatment in Japan reflects increasing clinical attention to substance-related behavioral concerns across young adults, working-age groups, and individuals with concurrent mental health needs. Treatment programs vary by substance type, severity of dependence, and patterns of polydrug use involving marijuana, alcohol, tobacco, and synthetic cannabinoids. Facilities offering care range from hospitals to rehabilitation centers, shaped by Japan’s structured healthcare system and preference for supervised interventions. The treatment mix includes counseling-based programs, detoxification support, and medication-assisted therapy for associated symptoms. This pattern shows how Japan addresses cannabis-related disorders within broader substance use frameworks, focusing structured environments, psychological support, and coordinated follow-up care.

By Type, Marijuana Accounts for the Largest Share of Treatment Demand

Marijuana accounts for 32.0% of treatment demand and remains the leading substance category for cannabis use disorder interventions in Japan. Increased exposure to imported cannabis products and illegal THC-containing items contributes to treatment entry within younger groups. Tobacco, nicotine, and vaping products represent 26.0%, reflecting overlapping dependence patterns identified during clinical assessments. Alcohol accounts for 18.0%, often appearing in co-occurring substance use cases requiring integrated support. Synthetic cannabinoids hold 14.0%, linked to adverse psychological effects that require monitored intervention. Other substances represent 10.0%, covering mixed or unclear-use cases. Distribution across substances shows how treatment professionals manage diverse dependence triggers and behavioral patterns.

Key points:

• Marijuana remains the primary substance requiring intervention.
• Tobacco/nicotine use overlaps with cannabis behaviors.
• Alcohol dependence appears in combined-use cases.
• Synthetic cannabinoids require focused clinical management.

By Treatment, Counselling and Behavioral Therapy Represents the Largest Share

Counselling and behavioral therapy accounts for 34.0% and remains Japan’s most used intervention for cannabis use disorder. These programs emphasize structured guidance, relapse prevention, and coping strategies suited to varying dependence levels. Detoxification represents 26.0%, applied when withdrawal symptoms or co-occurring use patterns require medical supervision. Medication accounts for 22.0%, focusing on associated anxiety, sleep disturbance, or comorbid mental health concerns. Support groups represent 18.0%, reflecting participation in peer-led programs that complement formal therapy. Treatment distribution shows how Japan applies a blended care model combining psychological support, supervised detox, and symptom-targeted pharmacologic strategies managed through regulated providers.

Key points:

• Counseling forms the core therapeutic approach.
• Detox programs address withdrawal risks and co-use.
• Medications target secondary symptoms.
• Support groups provide ongoing peer guidance.

By End User, Rehabilitation Centers Account for the Largest Share (41.0%)

Rehabilitation centers account for 41.0% and serve as Japan’s primary settings for cannabis use disorder treatment. These facilities provide structured programs, predictable routines, and monitored interventions suited to medium- and long-term recovery. Hospitals and clinics represent 37.0%, focusing on diagnosis, early-stage intervention, and cases requiring medical oversight. Other end users account for 22.0%, including counseling offices, community programs, and private support facilities offering varied engagement levels. End-user distribution reflects Japan’s focus on supervised, clinically guided environments supported by standardized assessment protocols and formal treatment pathways designed to manage dependence severity and prevent relapse.

Key points:

• Rehabilitation centers deliver structured recovery programs.
• Hospitals treat medically supervised cases.
• Other facilities provide flexible follow-up support.

What are the Drivers, Restraints, and Key Trends of the Demand for Cannabis Use Disorder Treatment in Japan?

Increased detection of cannabis-related offenses, rising referrals through the criminal justice system and expansion of prefectural addiction-consultation services are driving demand.

In Japan, demand for cannabis use disorder treatment is shaped by strict enforcement of the Cannabis Control Act, which leads police and regional prosecutors to refer offenders to medical and counselling services rather than rely solely on penal measures. Prefectures such as Tokyo, Osaka and Kanagawa have reported gradual increases in cannabis-related arrests among younger adults, prompting more evaluations at mental-health clinics. Public addiction-consultation centers operated by local governments provide free early-stage counselling, which increases treatment access for individuals identified through school, workplace or family interventions. These structural pathways contribute to steady demand for professional support services.

Strong social stigma, limited specialized treatment programs and reluctance among users to engage in clinical support restrain adoption.

Japan’s strict cultural norms around drug use create significant stigma, discouraging individuals from seeking help until legal involvement forces assessment. Few medical institutions offer specialized cannabis-focused treatment programs, and most substance-use services prioritize alcohol dependence, resulting in limited tailored interventions. Families may avoid contacting addiction services due to concerns about social consequences, reducing early engagement. These behavioural and systemic factors restrict treatment volume despite government efforts to promote early consultation.

Expansion of youth-focused prevention programs, increased involvement of psychiatric clinics and growth of confidential tele-counselling services define key trends.

Education boards in prefectures such as Tokyo, Saitama and Fukuoka are expanding drug-awareness programs targeting high school and university students, which increases early referrals for counselling. Psychiatric clinics are incorporating structured behavioural therapy and relapse-prevention tools tailored to younger adults who represent a growing share of cannabis cases. Tele-counselling platforms operated by local governments and nonprofit organizations provide confidential access to consultation, which reduces stigma-related barriers and encourages individuals to seek guidance without visiting clinics. These trends indicate slow but increasing institutional capacity for cannabis use disorder treatment within Japan.

Analysis of the Demand for Cannabis Use Disorder Treatment in Japan by Region

Demand for cannabis use disorder treatment in Japan is increasing through 2035 as healthcare providers, mental-health institutions, public-health agencies, and counseling services expand structured programs addressing substance-use behaviors. Treatment demand is shaped by regional healthcare capacity, awareness programs, and the gradual increase in individuals seeking behavioral-health support. Services typically include psychological counseling, outpatient interventions, cognitive-behavioral approaches, and coordinated care between hospitals and community clinics. Kyushu & Okinawa leads at 4.4%, followed by Kanto (4.1%), Kansai (3.6%), Chubu (3.1%), Tohoku (2.7%), and Rest of Japan (2.6%).

How is the Kyushu & Okinawa region driving demand for cannabis use disorder treatment?

Kyushu & Okinawa grows at 4.4% CAGR, supported by active regional health networks, rising patient engagement with mental-health services, and broad outreach programs conducted by municipal health offices. Prefectures such as Fukuoka, Kagoshima, and Kumamoto maintain structured addiction-treatment pathways involving psychiatric clinics, hospital outpatient units, and community counseling centers. Okinawa reports additional demand due to its younger demographic groups and strong presence of community-based support organizations, leading to higher screening participation. Public-health programs emphasize early intervention, encouraging individuals to seek behavioral guidance before symptoms escalate. Healthcare providers collaborate with local schools, welfare offices, and community programs to identify cases requiring structured counseling.

• Clinics offering behavioral-health interventions
• Community programs supporting early identification
• Hospitals providing outpatient treatment pathways
• Public-health offices expanding awareness and screening

How is the Kanto region shaping demand for cannabis use disorder treatment?

Kanto grows at 4.1% CAGR, influenced by high population density, extensive healthcare infrastructure, and strong integration of mental-health services across Tokyo, Kanagawa, Saitama, and Chiba. Urban clinics and psychiatric departments deliver structured therapy programs focused on behavioral modification and relapse-prevention strategies. Public-health centers conduct awareness campaigns focusing early consultation and confidential treatment access. Colleges and vocational schools in the region partner with mental-health professionals to support screening initiatives for young adults. Municipal welfare offices coordinate referrals to counseling specialists for long-term follow-up. Healthcare institutions in Tokyo maintain multidisciplinary teams that support case management and tailored intervention schedules.

• Mental-health clinics providing structured therapy
• Public-health centers conducting outreach initiatives
• Schools collaborating on behavioral-health screening
• Welfare offices coordinating treatment referrals

How is the Kansai region influencing demand for cannabis use disorder treatment?

Kansai grows at 3.6% CAGR, supported by established psychiatric-care networks, university communities, and municipal programs in Osaka, Kyoto, and Kobe. Healthcare providers offer counseling, behavioral-health evaluation, and continuing care for individuals seeking structured support. Student populations in Kyoto and Osaka create additional engagement with campus-linked counseling centers, which often serve as early points of contact. Local governments run awareness programs encouraging voluntary consultations. Hospitals in Osaka and Kobe maintain specialized outpatient mental-health units capable of providing long-term follow-up and coordinated psychotherapy. Community centers host informational workshops that address behavioral-health management and encourage early intervention.

• Hospitals offering long-term outpatient care
• University counseling centers supporting early engagement
• Municipal offices promoting voluntary consultation
• Community centers hosting behavioral-health workshops

How is the Chubu region contributing to demand for cannabis use disorder treatment?

Chubu grows at 3.1% CAGR, shaped by balanced urban-rural healthcare networks, consistent use of mental-health resources, and structured community-health programs across Nagoya, Shizuoka, and nearby prefectures. Psychiatric clinics offer therapy sessions focused on behavioral-adjustment support. Hospitals maintain outpatient mental-health departments that assist with structured treatment pathways. Municipal health offices conduct workshops encouraging early identification. Supervised counseling services are offered through welfare centers for individuals seeking confidential behavioral-health guidance. Distribution of informational materials through schools and community groups helps maintain awareness.

• Clinics delivering counseling and behavioral-health evaluation
• Hospitals managing outpatient treatment pathways
• Municipal offices conducting workshops on early intervention
• Welfare centers providing confidential support options

How is the Tohoku region shaping demand for cannabis use disorder treatment?

Tohoku grows at 2.7% CAGR, supported by regional healthcare networks, public-health initiatives, and reliance on community-level support services across Sendai, Akita, Aomori, and Fukushima. Households rely on local clinics for mental-health consultations, while hospitals provide structured outpatient treatment. Public-health centers integrate substance-use awareness programs into community events, promoting access to counseling. Rural areas depend on municipal welfare offices and tele-health channels for early behavioral-health evaluation. Educational institutions participate in preventive-education efforts targeting young populations.

• Local clinics offering initial behavioral support
• Hospitals providing structured outpatient follow-up
• Public-health centers promoting counseling access
• Rural welfare offices supporting early screening

How is the Rest of Japan region contributing to demand for cannabis use disorder treatment?

Rest of Japan grows at 2.6% CAGR, influenced by smaller population clusters, moderate availability of mental-health resources, and reliance on community-based interventions. Local clinics provide basic counseling and referral pathways to larger regional hospitals. Households access public-health consultations during community events, where screening and informational materials are distributed. Municipal offices coordinate support for individuals seeking long-term behavioral-health management. Schools and local welfare groups participate in preventive education to increase early awareness. Tele-health services support access in remote areas, ensuring continuity of care despite limited specialist availability.

• Clinics providing counseling and referral services
• Public-health programs promoting awareness in small communities
• Welfare groups supporting long-term behavioral-health management
• Tele-health channels enabling access in remote areas

What is the competitive landscape of cannabis use disorder treatment in Japan?

Demand for cannabis use disorder treatment in Japan is shaped by public institutions, psychiatric centers, and nationwide rehabilitation networks rather than pharmaceutical suppliers. The National Center of Neurology and Psychiatry (NCNP) holds an estimated 21.0% share of structured treatment activity through its Center for Dependence Disorders. The organization provides controlled psychological assessment, behavioural-therapy programmes, and evidence-based interventions aligned with national mental-health protocols.

The DARC Network maintains extensive coverage across prefectures, supporting individuals through residential and community-based rehabilitation programmes. These centers provide consistent counselling frameworks, peer-support environments, and relapse-prevention training, forming a core part of Japan’s non-medical treatment ecosystem. The Japanese Society of Psychiatry and Neurology (JSPN) contributes through clinical guidelines and practitioner support within hospitals and psychiatric clinics, ensuring a uniform approach to assessment and treatment of substance-use disorders, including cannabis use.

Prefectural Mental Health and Welfare Centers play a major role in early intervention, providing accessible counselling and case-management services for individuals referred through schools, families, or law-enforcement channels. Private psychiatric hospitals and addiction clinics add further capacity through structured outpatient treatment and cognitive-behavioural programmes adapted to individual clinical needs. Competition within Japan centers on clinical capacity, regional accessibility, therapeutic consistency, counselling quality, and coordination with public-health frameworks. Demand for treatment is shaped by strict legal enforcement, rising early-intervention initiatives, and increased counselling utilization, reinforcing the central role of public institutions and rehabilitation networks in managing cannabis use disorder within the country.

Key Players in Japan Cannabis Use Disorder Treatment Demand

• National Center of Neurology and Psychiatry (NCNP)
• Japan Alcohol and Drug Addiction Rehabilitation Center (DARC Network)
• Japanese Society of Psychiatry and Neurology (JSPN)
• Prefectural Mental Health and Welfare Centers
• Private psychiatric hospitals and addiction clinics

Scope of the Report

Japan Cannabis Use Disorder Treatment Demand by Segments

Type:

• Marijuana
• Tobacco/Nicotine and Vaping
• Alcohol
• Synthetic Cannabinoids
• Others

Treatment:

• Counselling & Behavioral Therapy
• Detoxification
• Medication
• Support Group

End User:

• Rehabilitation Centers
• Hospitals and Clinics
• Others

Region:

• Kyushu & Okinawa
• Kanto
• Kansai
• Chubu
• Tohoku
• Rest of Japan